Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Saved in:
| Title: | Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. |
|---|---|
| Authors: | Han K; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Jin JY; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Marchand M; Pharsight Consulting Services, Pharsight, a Certara™ Company, Marseille, France., Eppler S; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Choong N; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Hack SP; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Tikoo N; Statistical Programming Analysis, Genentech Inc, South San Francisco, CA, USA., Bruno R; Pharsight Consulting Services, Pharsight, a Certara™ Company, Marseille, France., Dresser M; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Musib L; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Budha NR; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA. budha.nageshwar@gene.com. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Nov; Vol. 76 (5), pp. 917-24. Date of Electronic Publication: 2015 Sep 13. |
| Publication Type: | Comparative Study; Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
